Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04611880 · ClinicalTrials.gov registry record · Phase 2
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
A Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT04611880: Active Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy, sponsored by Washington University School of Medicine.
NCT04611880 is a Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04611880, a Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is no treatment for RVCL. A maximum of 20 patients will be enrolled.
Primary Outcome
At each study time-point, the white matter hyperintensity lesion volume (mL) was normalized to whole-brain volume (mL) and then log-transformed, from which the annualized percent change in the log-transformed normalized WMH volume was calculated.
Conditions Studied
Interventions
- DRUG Crizanlizumab
Study Locations (2)
Missouri
- Andria Ford - St Louis
Pennsylvania
- Perelman School of Medicine; University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04611880 still lists
NCT04611880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy appearing as the primary indexed condition, and to 1 intervention - of which Crizanlizumab is the first listed.
NCT04611880 reports a single indexed study location in Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04611880 about?
NCT04611880 is a clinical study titled "Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)". This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is...
What is the current status of trial NCT04611880?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-01-25. Estimated completion is 2025-12-31.
What conditions does trial NCT04611880 study?
This clinical trial studies the following conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy.
What interventions are being tested in trial NCT04611880?
The interventions under investigation include: Crizanlizumab (DRUG).
Who is sponsoring clinical trial NCT04611880?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04611880 being conducted?
This trial has 2 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04611880's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI